IVIG Market Overview:
IVIG market (Intravenous Immunoglobulin Market) was valued at $7,861 million, and is expected to reach $12,632 million by 2022, supported by a CAGR of 7.1%. Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and specific in their action. They are obtained from blood by fractionation process and purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously in the treatment of various deficiencies.
Intravenous immunoglobulin market is driven by the increase in prevalence of chronic inflammatory demyelinating polyneuropathy and hypogammaglobulinemia, and rise in use of immunoglobulins to treat Guillain‐Barre syndrome, inflammatory myopathies, specific antibody deficiency, and others. Further, the increase in approval of intravenous immunoglobulin (IVIG) drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the sales of immunoglobulin. Increase in geriatric population and hemophilic patients, improved IVIG production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield) are the other key factors that contribute to the market growth. In addition, the market is restrained by the stringent government regulations, high cost of therapy, and high risk of side effects associated with the use of IVIG.
North America currently dominates the intravenous immunoglobulin market, in terms of revenue, followed by Asia-Pacific owing to high adoption of its treatments, high plasma collection, and large patient population. LAMEA is expected to growth at a high CAGR of 10% owing to the rise in preference of IVIG therapies and growth in awareness about immunodeficiency diseases in underdeveloped regions.
Key players operating in the IVIG industry are Baxter international Inc., CSL Ltd, Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc., and Bayer Healthcare.
MARKET DEFINITION AND SCOPE:
IVIGs are antibodies that are used in the treatment of patients suffering from antibody deficiencies. Currently, IVIG is used for several FDA- and European Medical Agency (EMA)-approved indications and several off-label indications; therefore, the report covers revenue generated from all these indications. IVIG therapy is used for indications such as hypogammaglobulinemia, immunodeficiency, CIDP, myasthenia gravis (MG), multifocal motor neuropathy (MMN), ITP, inflammatory myopathies, specific antibody deficiency (SAD), GBS, and others. Other applications include inflammatory myopathies and other off-label indications. The application market segment is deduced with the help of IVIG adoption pattern for each indication in different economies along with the incidence rate of these indications.
However, it does not include revenue generated from the SCIG consumption. The report does not consider the IVIGs used for research in academic institutes, and services provided by hospitals and clinics.
TOP INVESTMENT POCKETS:
Hypogammaglobulinemia, CIDP, and PID are the most lucrative application segments of the global IVIG market, which collectively accounted for ~50% of the overall market share in 2015. Emergence of potentially advanced technologies, such as recombinant biotechnology, along with the increase in acceptance of IVIG therapies, significantly impacts the market growth. Despite the high cost associated with IVIG therapy, hypogammaglobulinemia, CIDP, and immunodeficiency diseases remained the highest revenue-generating segments. The global market for hypogammaglobulinemia expected to grow with a CAGR of 6%. .
IgG replacement therapy is the most preferred treatment option for most immunodeficiency syndromes, namely X-linked, severe combined immunodeficiency, hyper-IgM, adenosine deaminase deficiency, common variable immunodeficiency (CVID), and Wiskott‐Aldrich syndrome. Key players such as CSL Ltd., Baxter International Inc., Grifols S.A., Octapharma Inc., and others focus on the development of IVIG therapies to treat various primary immunodeficiency diseases (PIDs). In accordance to the CIDP, IVIG treatment resulted in effective treatment for patients with a CIDP. Approximately, 40% of a patient’s CIDP treated with IVIG needed intermittent IVIG infusions to maintain improved clinical conditions, and it is further expected to be effective throughout the treatment. The global market for CIDP was valued at $1,629 million in 2015 and is expected to reach $2,452 million by 2022, growing at a CAGR of 6%.
IVIG MARKET, BY APPLICATION:
An IVIG preparation has inflammatory and immunomodulatory properties, which expand its traditional use to treat patients with primary immunodeficiency. It is successfully used to treat autoimmune and inflammatory conditions. IVIG preparations along with immunosuppressive agents or monoclonal antibodies are being focused on to increase the use of IVIG. For example, recent studies suggest that IVIG and rituximab (an anti-CD20 monoclonal antibody) combination therapy may be effective to treat autoimmune muco-cutaneous blistering diseases.
REGIONAL AND COUNTRY OVERVIEW:
North America and Asia-Pacific are the most lucrative regional market segments. The market growth of these segments is driven by the large patient population, favorable government policies, increase in purchasing power of the patient population in Asia-Pacific, and awareness about the immunodeficiency disease and other rare autoimmune disorders. U.S., Canada, and China are largest IVIG producers in the global IVIG market. The LAMEA IVIG market, however, is expected to the fastest growing region, growing at a CAGR of 10%. Factors such as increase in use of IVIG for off-label indications and rise in government initiative such as evaluation and development of orphan drugs to provide incentives for sponsors to develop products for rare disease are expected to fuel the growth of the IVIG market in the near future.
In Europe, the French IVIG market was valued at $299 million in 2015, and is expected to reach $474 million by 2022, with a CAGR of 6%.
KEY BENEFITS FOR STAKEHOLDERS:
- The study provides an in-depth analysis of the global intravenous immunoglobulin market to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the growth is provided.
- Projections are made by analyzing the current trends and future potential from 2014 to 2022, in terms of volume and value, that help identify the prevailing opportunities.
- The report covers in-depth analysis of all geographic regions. Government regulations regarding IVIG production and purification are discussed in detail.
- Competitive intelligence (of leading manufacturers) interprets the competitive scenario across various geographies.
IVIG Market Key Segments
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Immunodeficiency Diseases
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Idiopathic Thrombocytopenic Purpura (ITP)
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillain‐Barre syndrome
- North America
- Latin America
- Middle East
The key players that operate in the IVIG industry include Grifols S.A., CSL Behring Ltd., Baxter International Inc., Biotest AG, BDI Pharma Inc., China Biologic Products Inc., Kedrion Biopharma Inc., Octapharma AG., and LFB Group.